News
PVCT
0.153
-3.60%
-0.006
Weekly Report: what happened at PVCT last week (0610-0614)?
Weekly Report · 1d ago
Weekly Report: what happened at PVCT last week (0603-0607)?
Weekly Report · 06/10 10:09
Weekly Report: what happened at PVCT last week (0527-0531)?
Weekly Report · 06/03 10:11
Weekly Report: what happened at PVCT last week (0520-0524)?
Weekly Report · 05/27 10:13
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES POSTER PRESENTATION OF ROSE BENGAL SODIUM FOR TREATMENT OF FULL-THICKNESS CUTANEOUS WOUNDS AT SID 2024 ANNUAL MEETING
Reuters · 05/21 12:00
Weekly Report: what happened at PVCT last week (0513-0517)?
Weekly Report · 05/20 10:10
PVCT Stock Earnings: Provectus Reported Results for Q1 2024
Provectus (OTCMKTS:PVCT) just reported results for the first quarter of 2024. The company did not report any EPS for the quarter. ProvectUS reported revenue of $238,072. The company reported no earnings per share.
Investorplace · 05/15 01:54
Financial Report Articles: Comprehensive Analysis of Stock, Capital, and Earnings
Press release · 05/15 00:35
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES EIGHT PRESENTATIONS OF ROSE BENGAL PHOTODYNAMIC ANTIMICROBIAL THERAPY AT ARVO 2024 ANNUAL MEETING
Reuters · 05/14 12:00
Weekly Report: what happened at PVCT last week (0506-0510)?
Weekly Report · 05/13 10:15
Weekly Report: what happened at PVCT last week (0429-0503)?
Weekly Report · 05/06 10:19
Weekly Report: what happened at PVCT last week (0422-0426)?
Weekly Report · 04/29 10:23
Weekly Report: what happened at PVCT last week (0415-0419)?
Weekly Report · 04/22 10:17
Provectus Pharmaceuticals Announces New Leadership and Strategy
TipRanks · 04/16 21:12
Provectus appoints Pershing as CEO, Rodrigues as president
Healthcare Provectus appoints Pershing as CEO, Rodrigues as president. Ed Pershing appointed as CEO and Dominic Rodrigues will be president of the company. Provedctus Biopharmaceuticals, Inc. (PVCT) Stock.
Seeking Alpha · 04/16 15:05
Weekly Report: what happened at PVCT last week (0408-0412)?
Weekly Report · 04/15 10:12
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES PRESENTATION OF CANCER IMMUNOTHERAPY PV-10 POSTER FOR HNSCC AT AACR 2024 ANNUAL MEETING
Reuters · 04/11 12:00
Weekly Report: what happened at PVCT last week (0401-0405)?
Weekly Report · 04/08 10:15
Weekly Report: what happened at PVCT last week (0325-0329)?
Weekly Report · 04/01 10:14
Provectus Pharmaceuticals Strikes Key Ophthalmology Therapy Deal
TipRanks · 03/27 16:22
More
Webull provides a variety of real-time PVCT stock news. You can receive the latest news about Provectus Biopha through multiple platforms. This information may help you make smarter investment decisions.
About PVCT
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.